Experts outline treatment options for patients with venetoclax resistance.
Researchers sought to determine the results of first-line treatment of patients with primary mediastinal B-cell lymphoma.
Researchers described a case study that suggested ibrutinib may have beneficial effects in patients with acquired von Willebrand syndrome that is secondary to Waldenström macroglobulinemia.
Researchers sought for approval in Europe for obinutuzumab to be administered for a shorter, 90-minute infusion time among patients with previously untreated or previously treated follicular lymphoma.
Researchers sought to determine whether zanubrutinib would have a positive response in patients with relapsed/refractory marginal zone lymphoma.
Stopping treatment after induction did not impact disease-free survival in patients with undetectable minimal residual disease.
Researchers sought to determine whether lymphoma-associated macrophage counts could affect the prognosis of patients with MCL.
Time to next treatment was significantly longer with brentuximab vedotin.
A single-institution study determined the effect of a novel nursing practice on incidence of PICC-UEDVT, outcomes, and satisfaction with care in patients with NHL.
Transplant improved progression-free and overall survival at a median follow-up of 14 years.
Patients with DLBCL may be willing to travel longer distances for treatment if follow-up care was local, but this pattern varied by race.
Researchers sought to determine whether polatuzumab vedotin may be effective salvage or bridging treatment to CAR-T therapy for patients with relapsed/refractory LBCL.
Researchers sought to determine whether patients with B-NHL who had treatment with anti-CD20 antibodies had an impaired serological response to an mRNA COVID-19 vaccine.
Researchers sought to determine whether measures of inflammation would be associated with immune-related toxicities after CAR-T therapy.
Researchers sought to determine whether combining brentuximab vedotin with nivolumab would have positive PFS in patients with cHL.
Researchers sought to determine if treatment with lenalidomide could prevent CNS relapses in patients with DLBCL.
Researchers sough to assess the relationship between CD4/CD8 ratios and the risk for Kaposi sarcoma and non-Hodgkin lymphoma among patients with HIV infection treated with combination antiretroviral therapy.
The approval was based on data from 2 single-arm clinical trials in adults with relapsed or refractory marginal zone lymphoma who have received at least 1 anti-CD20-based regimen.
Researchers sought to determine whether combination therapy with temsirolimus and lenalidomide would have therapeutic activity in patients with heavily pretreated lymphomas.
Response and survival outcomes were similar with rituximab biosimilars and the originator.
Researchers sought to determine whether patients with relapsed or refractory classical Hodgkin lymphoma can receive benefit when retreated with nivolumab.
Researchers sought to determine whether patients with lymphoma would develop antibodies with a COVID-19 vaccine 6 months after treatment with anti-CD20-containing therapy.
Researchers sought to determine whether there is a role for extracellular vesicles associated with follicular lymphoma B cells in the alteration of bone marrow stroma.
Researchers sought to determine the fertility-related issues and approaches for survivors of Hodgkin lymphoma and diffuse large B-cell lymphoma.
Researchers sought to determine whether baseline SUVmax would have prognostic value in patients with follicular lymphoma.
A retrospective study revealed age-based risks for toxicities in patients with NHL treated with high-dose chemotherapy and autologous hematopoietic cell transplantation.
This case study showed that B-cell type primary central nervous system lymphoma may rapidly progress following dimethyl fumarate treatment in patients with relapsing remitting MS.
Circulating tumor DNA may identify patients at risk of relapse after axicabtagene ciloleucel.
Researchers sought to determine how chemoimmunotherapies can affect FDG-PET parameters and influence interpretation of results in patients with FL.
Researchers sought to determine whether patients with PCNSL who are not eligible for clinical trials may benefit from high-dose methotrexate.
Researchers sought to determine whether adding brentuximab vedotin to chemotherapy would be safe and effective in pediatric patients with ALCL.
Researchers sought to develop a low-cost, machine learning-based approach to diagnosing paraffin-embedded lymphoma biopsy specimens.
In a review, researchers explained diagnostic features associated with the rare condition of nodular lymphocyte-predominant Hodgkin lymphoma.
Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.
Researchers sought to determine whether the presence of LRPAP1 autoantibodies may predict clinical outcomes in patients with MCL.
Researchers sought to identify a new possible immune-related mechanism of action associated with chidamide for treatment of patients with PTCL.
Researchers sought to determine whether zanubrutinib would have a high response rate and extended progression-free survival in patients with R/R mantle cell lymphoma.
Researchers sought to determine whether a novel model that combines signatures of metabolic dysregulation with clinical features may aid in clinical decision-making among patients with DLBCL.
Researchers sought to determine whether fixed-duration chemotherapy-free treatment with obinutuzumab and idelalisib would be effective in patients with R/R WM.
Researchers sought to determine the maximum and recommended phase 2 dose for loncastuximab tesirine in patients with B-cell NHL.
Researchers are seeking to compare the efficacy and safety of the combination of ibrutinib and venetoclax compared with ibrutinib and placebo in patients with mantle cell lymphoma.
Researchers sought to determine which hematopoietic stem cell transplantation procedure is more efficacious for patients with refractory/relapsed peripheral T-cell lymphoma.
A review of the literature identified common deficits in cognitive functioning experienced by survivors of pediatric cancers.
Researchers sought to identify possible prognostic markers in extranodal natural killer T-cell lymphoma through an analysis of gene expression profiling data.
Researchers sought to determine whether first-line chemotherapy followed by high-dose therapy and auto-SCT would be the preferred treatment for patients under 60 with T-NHL.
In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5.
The overall response rate was 44.7% after a median follow-up of 15 months.
The median overall survival was not reached at 3 years.
The 7-year survival results were superior with MATRIX.
Relapsed/refractory disease and older age were also associated with prolonged hospital stay and death.
Researchers sought to identify factors that may contribute to failure with CAR T cell therapy in patients with LBCL.